Bolt Biotherapeutics Inc (BOLT)

$5.90 -0.35 (-5.60%)
Market Cap 12.00M
Revenue (ttm) 7.69M
Net Income (ttm) -63.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -820.81%
Debt to Equity Ratio 0.00
Volume 31,300
Avg Vol 38,208
Day's Range N/A - N/A
Shares Out 1.92M
Stochastic %K 3%
Beta 0.91
Analysts Sell
Price Target $6.00

Company Profile

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 665 9295
Address:
900 Chesapeake Drive, Redwood City, United States
HartFoundation
HartFoundation Jan. 29 at 4:47 PM
$BOLT bought 200 more shares.
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 28 at 8:32 PM
$BOLT 7.08/share. It wants to break this level. If it can, we moon.
0 · Reply
HartFoundation
HartFoundation Jan. 27 at 6:29 PM
$BOLT Been eyeing this forever, finally opened a position. GLTA.
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 27 at 4:31 PM
$BOLT 50 officially crossed 100 . 6.93/share and climbing on slow healthy volume. The explosion to the upside has to be soon. $15/share in cash, no debt, 50% insider and tute ownership, 2 assets in current partnership deals w/ big pharma Genmab and Toray, 3 assets (1 P1 and 2 pre-clincal) available for partnering, and main asset in Phase 1 dose escalation trial w/ initial data in Q3, already shown a strong immune response back in November. 1.92m SUPER LOW FLOAT. Epic set up :)
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 26 at 5:27 PM
$BOLT
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 26 at 4:23 PM
$BOLT 50 crossing 100, approaching 200SMA. Fireworks coming soon w/ volume.
0 · Reply
Red2Profit
Red2Profit Jan. 24 at 4:42 PM
$BOLT Strap in friends. About to break a weekly double bottom and falling wedge. Conservative target 10.39. Break those 52 week highs (12.60) and volume and we could see 25-32. Let's see how next week starts. Break and retest of 6.69 is key
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 23 at 8:05 PM
$BOLT This one is days away from exploding. 50 about to cross 100 SMA + volume
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 21 at 8:58 PM
$BOLT When the 50daySMA(yellow) crosses the 100daySMA(white) I expect a large pop to above $7. Looks like this may happen in the coming days/week. Then we are off to the races.
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 21 at 6:08 PM
$BCAB Everyone here got scammed by pumpers on multiple occasions. Come to $BOLT where cash is king, instead of this garbage company in risk of bankruptcy. I never bash stocks either, but this one is horrendous from 7 miles away.
0 · Reply
Latest News on BOLT
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 2 months ago

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Oct 1, 2025, 4:05 PM EDT - 4 months ago

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:05 PM EDT - 6 months ago

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 9 months ago

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

May 8, 2025, 8:00 AM EDT - 9 months ago

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Apr 30, 2025, 4:05 PM EDT - 9 months ago

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 10 months ago

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Mar 25, 2025, 4:30 PM EDT - 11 months ago

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 24, 2025, 4:20 PM EDT - 11 months ago

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Feb 25, 2025, 4:05 PM EST - 1 year ago

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Feb 11, 2025, 4:05 PM EST - 1 year ago

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Nov 7, 2024, 10:00 AM EST - 1 year ago

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Sep 6, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Bolt Biotherapeutics Announces Changes to its Board of Directors

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Announces Changes to its Board of Directors

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

Sep 4, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Sep 2, 2024, 11:11 AM EDT - 1 year ago

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

Sep 2, 2024, 11:00 AM EDT - 1 year ago

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 31, 2024, 11:25 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

Aug 31, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 29, 2024, 8:49 PM EDT - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

Aug 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm

Aug 27, 2024, 11:00 AM EDT - 1 year ago

A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

Jul 26, 2024, 10:00 AM EDT - 1 year ago

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Jul 25, 2024, 10:00 AM EDT - 1 year ago

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit

Jul 19, 2024, 11:10 AM EDT - 1 year ago

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Jul 3, 2024, 4:47 PM EDT - 1 year ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jun 24, 2024, 3:36 PM EDT - 1 year ago

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

May 17, 2024, 8:37 PM EDT - 1 year ago

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

HartFoundation
HartFoundation Jan. 29 at 4:47 PM
$BOLT bought 200 more shares.
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 28 at 8:32 PM
$BOLT 7.08/share. It wants to break this level. If it can, we moon.
0 · Reply
HartFoundation
HartFoundation Jan. 27 at 6:29 PM
$BOLT Been eyeing this forever, finally opened a position. GLTA.
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 27 at 4:31 PM
$BOLT 50 officially crossed 100 . 6.93/share and climbing on slow healthy volume. The explosion to the upside has to be soon. $15/share in cash, no debt, 50% insider and tute ownership, 2 assets in current partnership deals w/ big pharma Genmab and Toray, 3 assets (1 P1 and 2 pre-clincal) available for partnering, and main asset in Phase 1 dose escalation trial w/ initial data in Q3, already shown a strong immune response back in November. 1.92m SUPER LOW FLOAT. Epic set up :)
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 26 at 5:27 PM
$BOLT
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 26 at 4:23 PM
$BOLT 50 crossing 100, approaching 200SMA. Fireworks coming soon w/ volume.
0 · Reply
Red2Profit
Red2Profit Jan. 24 at 4:42 PM
$BOLT Strap in friends. About to break a weekly double bottom and falling wedge. Conservative target 10.39. Break those 52 week highs (12.60) and volume and we could see 25-32. Let's see how next week starts. Break and retest of 6.69 is key
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 23 at 8:05 PM
$BOLT This one is days away from exploding. 50 about to cross 100 SMA + volume
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 21 at 8:58 PM
$BOLT When the 50daySMA(yellow) crosses the 100daySMA(white) I expect a large pop to above $7. Looks like this may happen in the coming days/week. Then we are off to the races.
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 21 at 6:08 PM
$BCAB Everyone here got scammed by pumpers on multiple occasions. Come to $BOLT where cash is king, instead of this garbage company in risk of bankruptcy. I never bash stocks either, but this one is horrendous from 7 miles away.
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 20 at 6:17 PM
$BOLT Once the volume comes in, this will blast off well beyond 7.18
0 · Reply
JDD808
JDD808 Jan. 19 at 11:39 PM
$BOLT let’s reclaim 7.18 and beyond
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 19 at 11:20 AM
$BOLT Current Stock Price: $6.36
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 16 at 5:08 PM
$BOLT The proverbial dump before the pump
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 16 at 4:24 PM
$BOLT My last correspondence with the CEO and IR was back in October when I asked about partnership negotiations for BDC-3042 and I was told 'we continue to have discussions'. Before that October email, IR would regularly respond to my questions. I haven't sent them any emails since October until 2 weeks ago, asking for updates...no response. I tried again about 3 days ago, still no response. Normally they respond within 24 hours.....perhaps something being worked on behind the scenes. The company has been awfully quiet lately. The last filing they posted was in December giving all of their management fresh stock options :)
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 15 at 8:04 PM
$BOLT
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 14 at 6:02 PM
$BOLT People are finally starting to catch on here. Only a matter of time. 1.92m super LOW FLOAT w/ 50% locked by Tutes/Insiders. $15/share in cash, no debt, partnership w/ big pharma, and multiple assets looking to partner. $30 minimum on this IMO. Has potentially to fly way higher on high volume. 6.70 --> 7.70 --> 9.50 --> then no limit
2 · Reply
JDD808
JDD808 Jan. 14 at 4:21 PM
$BOLT holding this one strong from 4.96
0 · Reply
Lukey63
Lukey63 Jan. 14 at 3:32 PM
$BOLT Break out? And $20 cash per share on BS. Right up my alley.
0 · Reply
kshonstocks
kshonstocks Jan. 14 at 3:15 PM
$BOLT has the higher highs on chart
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 13 at 6:50 PM
$BOLT Short interest has dropped off rapidly since March. I've never seen a short interest at only 352 lmao! Shorts know not to mess around w/ this one! Been in partnership diligence talks since non-binding term sheets were requested in May for BDC-3042
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 13 at 3:36 PM
$BOLT Updated as recently as December. Don't forget. 3 programs seeking partnership all had good data readouts + two programs already partnered w/ big pharma companies Genmab and Toray. All the while trading at a cash value of $15/share. This is a buyout contender 100% imo. I've been loading the boat for months I think the time is sooner rather than later.
0 · Reply